Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

on, which
is a counter-reaction of the body potentially decreasing the efficacy of current drug therapy1. In contrast to small molecule inhibitors, which display large variations in serum drug levels throughout the day, the vaccine-induced anti-angiotensin II antibodies were found to decline with a half-life of about 4 months. This may lead to a practically continuous inhibition of angiotensin II for weeks, which may in part account for the minor reactive rise observed in plasma renin concentration, and to the potent effect of the vaccine in early morning hours, as is further explained in the quote of Dr. Müller below.

A further important finding of the study is the dependence of efficacy on both the dose of the vaccine and the levels of induced anti-angiotensin II antibodies. Two doses of the vaccine, 100 ?g and 300 ?g, were tested in the trial. The induced anti-angiotensin antibody levels were significantly higher at the 300 ?g than at the 100 ?g dose (p=0.0098). Accordingly, blood pressure reduction was much larger and only significant at the 300 ?g dose (p=0.0498). Efficacy was thus driven by a longlasting, although reversible antibody response. Dr. Philipp Müller, EVP Clinical Development at Cytos Biotechnology comments on the study results:

“These data highlight a very important new aspect of the vaccine CYT006-AngQb, namely its exceptionally good control of the early morning blood pressure. So far, inhibition of the reninangiotensin system has been studied clinically only with small molecule inhibitors, which all produce a daily pattern of peaks and troughs in drug levels. Here, a trough in drug levels coincides with a natural rise of the blood pressure in early morning hours. The combination of these effects may lead to insufficient control of the early morning blood pressure surge. An intervention with a different pharmacokinetic profile like the vaccine approach, which avoids daily peaks and troughs in drug l
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... that it has received final approval for its common shares ... Exchange (the "TSX"). The Company,s common shares will commence trading ... under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares will ... About ESSA Pharma Inc. ESSA Pharma is a ...
(Date:7/28/2015)... 2015 According to a new market ... Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration ... to 2020", published by MarketsandMarkets, the European Injectable Drug Delivery ... $114.7 Billion in 2015, growing at a CAGR of 12.6% ... 230 market data T ables and ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
(Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Fertility specialist ... as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors ... hundreds of her esteemed colleagues and peers in the metro area as one of ...
(Date:7/28/2015)... ... 28, 2015 , ... A new study published by HealthDay News on June ... light on a possible new treatment option for people living with fibromyalgia – hyperbaric ... at least five per week, patients experienced a significant decrease in pain, fatigue, and ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... lead to cognitive problems , , FRIDAY, Dec. 19 (HealthDay ... matter in a fetus, frontal and occipital lobes, which ... processing. The finding may help explain problems seen in ... says. , "The brain,s white matter is made up ...
... ultrasound device, developed by a Cornell graduate student, fits in ... punch to stabilize a gunshot wound or deliver drugs to ... called a transducer, and it creates sound waves so strong ... steam., Tinkering in his Olin Hall lab, George K. Lewis, ...
... hold the secret to eradicating malaria or schistosomiasis? ... is utilizing the combination of algorithms and models ... in the fight against infectious diseases. , Professor ... and analyze symptoms, treatment outcomes and environmental conditions ...
... with thoughts of getting in shape and improving our health, yet without ... fall by the wayside rather quickly. With a team approach, the ... tips to ensure success for a new and improved you in the ... ...
... program during holidays and economic challenges , ... ... provider of medical information and retail products understands the tough ... said "with the economy in shambles and millions of people ...
... the largest grant in its history: $24.4 million from ... cultural disparities in oral health. , The seven-year ... of Dental and Craniofacial Research, will enable the UCSF ... CAN DO) to launch new programs in preventing early ...
Cached Medicine News:Health News:Moms-to-Be Who Drink May Damage Fetus' White Matter 2Health News:Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis 2Health News:Case Western Reserve professor helps control infectious diseases with models and math 2Health News:Case Western Reserve professor helps control infectious diseases with models and math 3Health News:Case Western Reserve professor helps control infectious diseases with models and math 4Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 2Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 3Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 4Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 5Health News:Health Tips for the New Year; Patience and Persistence will Payoff; Key Advice from the Wellness Team at D.I.S.C. Sports and Spine Center 6Health News:UCSF receives $24.4 million to fight early childhood cavities 2
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: